摘要
目的探讨不同剂型紫杉醇联合顺铂治疗晚期卵巢癌患者的临床疗效。方法选取2016年7月至2021年5月间西北妇女儿童医院收治的116例晚期卵巢癌患者,根据随机信封抽签原则分为研究组和对照组,每组58例。对照组患者采用紫杉醇注射液联合顺铂治疗,研究组患者采用白蛋白结合型紫杉醇联合顺铂治疗,比较两组患者血清肿瘤标志物和T淋巴细胞亚群变化情况。结果研究组客观有效率为82.8%,高于对照组的62.1%,差异有统计学意义(P<0.05)。两组患者治疗期间的不良反应主要为肝肾反应、胃肠道反应、血液学反应和皮肤反应等,发生率比较,差异均无统计学意义(P>0.05)。治疗后,两组患者卡氏功能(KPS)评分均升高,免疫功能评分均降低,且研究组KPS评分高于对照组,免疫功能评分低于对照组,差异均有统计学意义(均P<0.05)。治疗后,两组患者血清鳞状细胞癌相关抗原和细胞角蛋白19片断抗原水平均低于治疗前,且研究组均低于对照组,差异均有统计学意义(均P<0.05)。治疗后,两组患者CD8+T淋巴细胞、CD4+CD25+T淋巴细胞比例均高于治疗前(P<0.05),且研究组高于对照组,差异均有统计学意义(均P<0.05)。结论相对于紫杉醇注射液,白蛋白结合型紫杉醇联合顺铂在晚期卵巢癌中应用,能抑制血清肿瘤标志物释放,改善患者免疫功能,提高近期疗效,缓解临床症状,且不会增加不良反应。
Objective To investigate efficacy of different dosages of paclitaxel combined with cisplatin in patients with advanced ovarian cancer.Methods From July 2016 to May 2021,116 patients with advanced ovarian cancer diagnosed and treated at Northwest Women’s and Children’s Hospital were selected.The patients were divided into an experimental group and a control group with 58 patients each using random envelope drawing.Patients in the experimental group received albumin-bound paclitaxel combined with cisplatin and patients in the control group received paclitaxel injection combined with cisplatin.The changes in serum tumor markers and T lymphocyte subsets were compared between the two groups.Results The objective efficacy rate was 82.8%in the experimental group,which was higher than the 62.1%of the control group(P<0.05).There were no statistically significant difference in the incidence of adverse reactions including liver and kidney,gastrointestinal,hematological and skin reactions between the two groups during the treatment period(P>0.05).After treatment,Karnofsky performance status(KPS)score increased and Eastern Cooperative Oncology Group(ECOG)score decreased in the two groups and KPS score was higher in the experimental group than in the control group and ECOG was lower in the experimental group than in the control group(all P<0.05).The serum squamous cell carcinoma associated antigen(SCCA)and Cytokeratin 19 fragment antigen(Cyfra)21-1 levels decreased in the two groups after the treatment with the experimental group lower than the control group(all P<0.05).The percentage of CD8+and CD4+CD25+T lymphocytes increased in the two groups after treatment with were the experimental group higher than the control group(all P<0.05).Conclusion Compares with paclitaxel injection,albumin-bound paclitaxel combined with cisplatin can inhibit the release of serum tumor markers,improve function of the immune system and short-term efficacy,and promote the relief of clinical symptoms without increasing adverse reactions in advan
作者
张亚妮
肖竹维
刘振国
齐进
ZHANG Ya-ni;XIAO Zhu-wei;LIU Zhen-guo;QI Jin(Department of Pharmacy,Northwest Women's and Children's Hos pital,Xi'an 710061,China;First Department of Gynecology,Northwest Women's and Children's Hos pital,Xi'an 710061,China)
出处
《中国肿瘤临床与康复》
2022年第5期568-572,共5页
Chinese Journal of Clinical Oncology and Rehabilitation
